Last reviewed 2026-06-01 · How we verify

Lidepran (LEVOFACETOPERANE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Lidepran (generic name: LEVOFACETOPERANE) is a levofacetoperane drug. It is currently in Phase 2 development.

Lidepran works by interacting with a specific molecular target to produce its therapeutic effects.

Lidepran is a small molecule with the synonyms LEVOFACETOPERANE, LEVOFACETOPERANO, LEVOPHACETOPERANE, and RP-8228.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LEVOFACETOPERANE
Drug class	levofacetoperane
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Lidepran has a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how Lidepran works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lidepran CI brief — competitive landscape report
Lidepran updates RSS · CI watch RSS

Frequently asked questions about Lidepran

What is Lidepran?

Lidepran (LEVOFACETOPERANE) is a levofacetoperane drug.

How does Lidepran work?

Lidepran works by interacting with a specific molecular target to produce its therapeutic effects.

What is the generic name of Lidepran?

LEVOFACETOPERANE is the generic (nonproprietary) name of Lidepran.

What drug class is Lidepran in?

Lidepran belongs to the levofacetoperane class. See all levofacetoperane drugs at /class/levofacetoperane.

What development phase is Lidepran in?

Lidepran is in Phase 2.

Drug class: All levofacetoperane drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing